Long-Time Novavax Board Member Jack Marsh Assumes Role of Director Emeritus
June 18 2014 - 4:40PM
Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical
company focused on the discovery, development and commercialization
of recombinant nanoparticle vaccines and adjuvants, today announced
that on June 12, 2014, the Honorable John O. Marsh, Jr., resigned
as a member of its Board of Directors. Mr. Marsh joined the Board
of Novavax in August 1991 and served as the company's interim CEO
and Chairman of the Board from 1996 to 1997. At various times
during his 23 years as a Board member, he has served on all of the
Board's various committees. According to company records kept since
2005, Jack's attendance rate at Board meetings was in excess of
90%; Mr. Marsh has attended every board of directors meeting in
person or by telephone since 2010. In recognition of his 23 years
of service, the Board of Directors has named Mr. Marsh Director
Emeritus.
A lifetime resident of Virginia, Mr. Marsh served in the U.S.
Army during World War II and continued with the Army Reserve and
Army National Guard into the 1960s. A graduate of Washington and
Lee University Law School, Mr. Marsh began practicing law in 1952
in a variety of state and municipal roles. From 1963 until 1971 he
served as a member of the U.S. House of Representatives. In 1973,
he was appointed Assistant Secretary of Defense, and in January
1974, became the National Security Advisor for then Vice President
Gerald Ford. He subsequently became President Ford's
cabinet-ranking Counsellor to the President. In 1981, Mr. Marsh was
appointed Secretary of the Army by President Ronald Reagan where he
served until 1989. Mr. Marsh has been awarded the Department of
Defense Distinguished Public Service Award on six occasions and was
awarded the Presidential Citizens Medal from President Reagan. Mr.
Marsh has been a Professor of Law and Ethics at various
institutions including the Virginia Military Institute, the College
of William & Mary, and George Mason University. He currently
resides in Winchester, Virginia with his wife.
"Jack's legacy as a board member of Novavax cannot be
underestimated. His leadership at this company paved the way for
our recent years of successful vaccine development," stated Stanley
C. Erck, President and CEO. "Jack's enthusiasm for the company's
business and his continued presence on the Board through some very
difficult early years has allowed Novavax to become a leading
recombinant vaccine development company and to make sustained
progress in our development of important recombinant vaccine
candidates. I am delighted that Jack has agreed to serve as a
director emeritus to the Board where he can continue to mentor and
advise the other members of the Board, as well as our senior
management team."
Chairman of the Board James F. Young, Ph.D. stated, "I am
honored and privileged to have served on the Novavax Board of
Directors with Jack Marsh. Over the last four years, I have learned
a great deal about the company's history and about boardroom
decision-making and diplomacy, witnessing Jack's firm and confident
presence in our boardroom. I am proud to call Jack a friend, and I
look forward to working with him in the future."
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage
biopharmaceutical company creating vaccines and vaccine adjuvants
to address a broad range of infectious diseases worldwide. Using
innovative proprietary recombinant nanoparticle vaccine technology,
the company produces vaccine candidates to efficiently and
effectively respond to both known and newly emergent diseases.
CONTACT: Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Novavax, Inc.
240-268-2000
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Apr 2023 to Apr 2024